DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pharmacokinetics of Dalteparin in Patients With Impaired Renal Function

Information source: Luzerner Kantonsspital
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Renal Insufficiency

Phase: Phase 4

Status: Completed

Sponsored by: Luzerner Kantonsspital

Official(s) and/or principal investigator(s):
Pirmin Schmid, MD, Principal Investigator, Affiliation: Luzerner Kantonsspital, Hematology
Andreas G Fischer, MD, Study Director, Affiliation: Luzerner Kantonsspital, Nephrology
Walter A Wuillemin, MD, PhD, Study Chair, Affiliation: Luzerner Kantonsspital, Hematology


Low molecular weight heparins (LMWH) have been shown to be at least as efficient and safe as unfractioned heparin (UFH) in prophylaxis and treatment of venous thromboembolic events and in therapy of acute cardiovascular diseases. LMWH are widely used as safe replacement of oral anticoagulation with vitamin K antagonists (VKA). Due to their pharmacokinetic characteristics, LMWH tend to accumulate in patients with impaired renal function. Official guidelines recommend therefore to use LMWH controlled by Anti-Xa levels or to use UFH instead of LMWH to provide full therapeutic anticoagulation therapy in patients with severe renal insufficiency. Although dosage recommendations have been proposed for enoxaparin in patients with renal impairment based on several studies, these data cannot be applied to other LMWH directly due to different pharmacokinetic properties of each drug. The present study aims to clarify the pharmacokinetics of dalteparin in patients with renal insufficiency, especially addressing the question of accumulation after multiple doses and including patients with severe renal insufficiency and derive a safe and suitable concept for using dalteparin in patients with impaired renal function.

Clinical Details

Official title: Pharmacokinetics of Dalteparin in Patients With Impaired Renal Function

Study design: Observational Model: Cohort, Time Perspective: Prospective


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Patient starting with dalteparin for prophylaxis OR therapy by order of the treating

physician (after having evaluated clinical indication and contraindications).

- Renal function normal OR impaired with or without dialysis therapy according to open

study groups

- Age >= 18 years

- Written informed consent

Exclusion Criteria:

- Pregnancy / Lactation

- Dalteparin or other LMWH already in use for > 1 day, unless just in use during


- Anti-Xa level before first application of dalteparin > 0. 3 U / ml

- Participation in another study

- Anuria OR glomerular filtration rate < 10 ml/min without dialysis

- Patient on intensive care unit (ICU)

- Cardiovascular unstable patient or probable need for a quick stop of anticoagulation

(e. g. emergency surgery)

- Patient with a disease whose estimated life expectancy is < 28 days

Locations and Contacts

Kantonsspital Luzern, Luzern, LU 6000, Switzerland
Additional Information

Luzerner Kantonsspital, Hematology

Luzerner Kantonsspital, Nephrology

Pirmin Schmid

Related publications:

Schmid P, Fischer AG, Wuillemin WA. Low-molecular-weight heparin in patients with renal insufficiency. Swiss Med Wkly. 2009 Aug 8;139(31-32):438-52. doi: smw-11284. Review.

Starting date: January 2006
Last updated: January 25, 2010

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017